Chloropentafluorobenzene is a colorless liquid with a pungent odor. It is synthesized by the reaction of pentafluorobenzene with chlorine in the presence of a Lewis acid catalyst. Chloropentafluorobenzene is used as a building block in the synthesis of various fluorinated compounds. Its importance lies in its unique reactivity profile, which stems from the presence of both electron-withdrawing fluorine atoms and an electron-donating chlorine atom. This combination of properties makes it a versatile intermediate for the preparation of diverse fluorinated materials. Chloropentafluorobenzene has potential applications in areas such as pharmaceuticals, agrochemicals, and materials science. Studies on chloropentafluorobenzene focus on its reactivity, its use in the development of new synthetic methods, and its potential applications in various fields.'
| ID Source | ID |
|---|---|
| PubMed CID | 9579 |
| SCHEMBL ID | 219009 |
| MeSH ID | M0189427 |
| Synonym |
|---|
| EN300-19366 |
| c6clf5 |
| chloroperfluorobenzene |
| einecs 206-450-6 |
| nsc 96886 |
| ccris 2394 |
| 1-chloro-2,3,4,5,6-pentafluorobenzene |
| 344-07-0 |
| pentafluorochlorobenzene |
| pentafluorophenyl chloride |
| nsc-96886 |
| benzene, chloropentafluoro- |
| nsc96886 |
| chloropentafluorobenzene |
| chloropentafluorobenzene, 99% |
| P0850 |
| STK802037 |
| AKOS005622682 |
| unii-3d8a2ye2u8 |
| 3d8a2ye2u8 , |
| benzene, 1-chloro-2,3,4,5,6-pentafluoro- |
| FT-0623686 |
| SCHEMBL219009 |
| BBL027298 |
| pentafluorophenylchloride |
| DTXSID4059837 |
| 1-chloro-2,3,4,5,6-pentafluorobenzene # |
| benzene, chloro pentafluoro- |
| mfcd00000534 |
| Q26840781 |
| 1-chloranyl-2,3,4,5,6-pentakis(fluoranyl)benzene |
| AMY12524 |
| FS-4016 |
| pentafluoro-1-chlorobenzene |
| D92026 |
| CS-0121203 |
| 2,3,4,5,6-pentafluorochlorobenzene |
| Z104473642 |
Chloropentafluorobenzene (CPFB) has been identified as a candidate simulant for nonpersistent chemical warfare agents.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Chloropentafluorobenzene (CPFB) has been proposed as an innocuous simulant for the uptake of toxic gases. " | ( A physiologically based pharmacokinetic model for chloropentafluorobenzene in primates to be used in the evaluation of protective equipment against toxic gases. Crank, WD; Vinegar, A, ) | 1.83 |
| "Chloropentafluorobenzene (CPFB) has been identified as a candidate simulant for nonpersistent chemical warfare agents. " | ( Effects of a 13-week chloropentafluorobenzene inhalation exposure of Fischer 344 rats and B6C3F1 mice. Bunger, SK; Flemming, CD; Grabau, JH; Kimmel, EC; Kinkead, ER; Wall, HG, 1991) | 2.04 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " To understand the relationship between exposure and measurement, we have developed a physiologically-based pharmacokinetic (PB-PK) model for CPFB in primates." | ( A physiologically based pharmacokinetic model for chloropentafluorobenzene in primates to be used in the evaluation of protective equipment against toxic gases. Crank, WD; Vinegar, A, ) | 0.38 |
| " A risk assessment for chloropentafluorobenzene (CPFB) was performed in which a physiologically based pharmacokinetic model was employed to calculate an internal measure of effective tissue dose appropriate to each toxic endpoint." | ( Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. Clewell, HJ; Jarnot, BM, 1994) | 0.83 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||